BRINTELLIX VORTIOXETINE
LIVE

Serial Number

79134889

Owner

H. Lundbeck A/S

Attorney

Claudia A. Smith

Filing Date

Nov 28, 2012

Add to watchlist:

No watchlists yet
View on USPTO

BRINTELLIX VORTIOXETINE Trademark

Serial Number: 79134889 • Registration: 4642921

BRINTELLIX VORTIOXETINE is a trademark filed by H. Lundbeck A/S on November 28, 2012. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

H. Lundbeck A/S (398 trademarks)

Ottiliavej 9
DK-2500 Copenhagen-Valby , DK

Entity Type: 03

Trademark Details

Filing Date

November 28, 2012

Registration Date

November 25, 2014

Published for Opposition

September 9, 2014

Cancellation Date

October 23, 2020

Goods & Services

Surgical, medical, dental and veterinary apparatus and instruments; suture materials; medical apparatus and instruments for diagnostic purposes, namely, apparatus for medical diagnostic testing for diseases and disorders of the central nervous system; integrated medical examination systems comprising medical instruments, hardware and software for information and information management for use of a web-based physical and psychological examination and assessment of patients and information, guidance and control of medicines

Educational and training services, namely, seminars, conferences, symposiums, workshops, courses, classes and lectures in the field of research and development, science, clinical tests, medical diagnostics, medicine, pharmaceuticals, disorders, diseases, treatments and prevention; educational and training services, namely, seminars, conferences, symposiums, workshops, courses, classes and lectures in the field of research and development, science, clinical tests, medical diagnostics, medicine, pharmaceuticals, disorders, diseases, treatments and prevention provided electronically, on-line, via cable or Internet or other electronic media; providing non-downloadable on-line publications, namely, books, reports, brochures, booklets, leaflets, leaflets containing patient information, magazines, journals, teaching and educational material in the field of research and development, science, clinical tests, medical diagnostics, medicine, pharmaceuticals, disorders, diseases, treatments and prevention; Entertainment services, namely, organizing, arranging, and conducting running, walking, golf, tennis, softball, and cycling events and cultural activities

Scientific apparatus and instruments, namely, magnetic, electronic and optical data carriers containing information and data in the fields of research and development, science, clinical tests, medical diagnostics, medicine, pharmaceuticals, disorders, diseases, treatment and prevention; pre-recorded audio cassettes, pre-recorded video cassettes, and electronic and digital media featuring information and data in the fields of research and development, science, clinical tests, medical diagnostics, medicine, pharmaceuticals, disorders, diseases, treatment and prevention; downloadable electronic publications, namely, books, reports, brochures, booklets, leaflets, patient information leaflets, magazines, journals, teaching and educational material, in the field of research and development, science, clinical tests, medical diagnostics, medicine, pharmaceuticals, disorders, diseases, treatment and prevention; recorded computer software, namely, software for searching, storing, cataloging, and indexing medical and pharmaceutical information, indexing education and sales activities, and for enabling web-based access to websites, enabling database integration, and enabling web searching of websites, intranet and Internet; software that provides web-based access to applications and services through a web operating system or portal interface, software to provide web-based electronic storage and display of digital information in the fields of research and development, science, clinical tests, medical diagnostics, medicine, pharmaceuticals, disorders, diseases, treatment and prevention in the form of sounds, noises, images, graphics, animated graphics, texts, movies, and databases; data processing equipment and computers; downloadable application software for downloading information on the use of pharmaceutical products and on diseases and disorders of the central nervous system and the treatment thereof; downloadable software for games which provide information related to diseases and disorders of the central nervous system and the treatment thereof; and downloadable mobile applications for transmitting, sharing, receiving, downloading, displaying and transferring content, text, visual works, audio works, audiovisual works, literary works, data, files, documents and electronic works via portable and handheld electronic devices and computers in the fields of research and development, science, clinical tests, medical diagnostics, medicine, pharmaceuticals, disorders, diseases, treatment and prevention

Pharmaceutical preparations for the prevention and treatment of disorders and diseases in or affecting the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of disorders and diseases generated by or acting on the central nervous system; pharmaceutical preparations and substances acting on the central nervous system to treat or prevent disorders and diseases in or affecting the central nervous system; central nervous system stimulants; pharmaceutical preparations and substances for the prevention and treatment of psychiatric and neurological disorders and diseases; pharmaceutical preparations and substances for the prevention and treatment of Alzheimer's disease and disorder, depression, psychosis, anxiety, epilepsy, multiple sclerosis, porphyria, Huntington's disease and disorder, insomnia, Parkinson's disease and disorder, schizophrenia, bipolar disorder and disease, oncology, pain, alcoholism and addiction; preparations, substances, reagents and agents for diagnostic and medical purposes; all the foregoing containing in whole or substantial part vortioxetine

Medical services; medical services in the field of psychiatry and psychology; medical advisory and information services concerning medical and pharmaceutical preparations and substances; medical clinical services; medical treatment services; therapeutic treatment services, namely, providing therapeutic services to persons in need of treatment for conditions, disorders or diseases of the central nervous system; healthcare and medical services related to central nervous system disorders, diseases and pharmaceuticals; providing for medical and medicinal information in the field of diagnostic, medicine, medical dose, pharmaceuticals, disorders, diseases, treatments and prevention; all the aforementioned services provided off-line as well as on-line

Scientific and technological services, namely, scientific research, analysis and testing in the field of pharmaceuticals and research and design relating thereto; industrial research in the field of pharmaceuticals; design and development of computer hardware and software; providing a website featuring non-downloadable software that allows users to view scientific data and information in the field of research and development, science, clinical tests, diagnostic, medicine, pharmaceuticals, disorders, diseases, treatments and prevention; pharmaceutical research and development; scientific and technological services, namely, scientific research, analysis, and testing in the field of disorders, diseases and prevention; scientific and technological services, namely, scientific research, analysis, and testing in the field of the central nervous system and central nervous system related disorders, diseases and pharmaceuticals; medical research; providing medical and clinical testing services for research purposes in the fields of central nervous system research and research on central nervous system related disorders, diseases and pharmaceuticals; providing scientific research information in the fields of central nervous system research and research on central nervous system related disorders, diseases and pharmaceuticals; providing scientific testing in the fields of central nervous system research and research on central nervous system related disorders, diseases and pharmaceuticals; providing medical and medicinal research information in the fields of central nervous system research and research on central nervous system related disorders, diseases and pharmaceuticals

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Nov 7, 2020 DENC
DEATH OF INTERNATIONAL REGISTRATION
Nov 7, 2020 DETH
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Nov 25, 2019 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
May 8, 2015 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Apr 20, 2015 FICS
FINAL DISPOSITION PROCESSED
Apr 20, 2015 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Feb 25, 2015 FICR
REGISTERED-PRINCIPAL REGISTER
Nov 25, 2014 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 9, 2014 NPUB
PUBLISHED FOR OPPOSITION
Sep 9, 2014 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Aug 20, 2014 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Aug 7, 2014 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 5, 2014 CNSA
EXAMINER'S AMENDMENT ENTERED
Aug 4, 2014 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Aug 4, 2014 GNEN
EXAMINERS AMENDMENT E-MAILED
Aug 4, 2014 GNEA
EXAMINERS AMENDMENT -WRITTEN
Aug 4, 2014 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 30, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 30, 2014 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 30, 2014 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jun 12, 2014 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jun 12, 2014 REAP
UNRESPONSIVE/DUPLICATE PAPER RECEIVED
Apr 24, 2014 UNPR
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 24, 2014 CRFA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 16, 2014 TCCA
TEAS VOLUNTARY AMENDMENT RECEIVED
Apr 16, 2014 PARI
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Feb 5, 2014 GNRN
NON-FINAL ACTION E-MAILED
Feb 5, 2014 GNRT
NON-FINAL ACTION WRITTEN
Feb 5, 2014 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 23, 2014 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 23, 2014 CRFA
ASSIGNED TO LIE
Jan 21, 2014 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 8, 2014 TROA
REFUSAL PROCESSED BY IB
Sep 30, 2013 RFNT
APPLICATION FILING RECEIPT MAILED
Sep 10, 2013 MAFR
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 9, 2013 RFCS
REFUSAL PROCESSED BY MPU
Sep 9, 2013 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 7, 2013 RFCR
NON-FINAL ACTION WRITTEN
Sep 6, 2013 CNRT
ASSIGNED TO EXAMINER
Sep 4, 2013 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 4, 2013 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Sep 3, 2013 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Aug 29, 2013 REPR